Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders
Gayle Wittenberg(Johnson & Johnson (United States)), Wayne C. Drevets(Johnson & Johnson (United States)), Edward T. Bullmore(King's College London), Benjamin Hsu(Janssen (United States)), P. S. Jagannatha(GlaxoSmithKline (India)), Guang Chen(Chengdu University of Traditional Chinese Medicine), Yun Zhang(Janssen (Belgium)), Yu Sun(Janssen (United States)), Dai Wang(Janssen (United States)), Ashutosh Gupta(GlaxoSmithKline (India)), Annie Stylianou(GlaxoSmithKline (United Kingdom)), Mark Curran(Janssen (United States)), Shahid A. Khan(Imperial College London)
Cited by 191
Related Papers
Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science
|The Lancet Psychiatry|2020|6k
Network-based statistic: Identifying differences in brain networks
|NeuroImage|2010|2.8k
Subgenual prefrontal cortex abnormalities in mood disorders
|Nature|1997|2.7k
Efficiency and Cost of Economical Brain Functional Networks
|PLoS Computational Biology|2007|2.6k
A Resilient, Low-Frequency, Small-World Human Brain Functional Network with Highly Connected Association Cortical Hubs
|Journal of Neuroscience|2006|2.5k